The utilization of next generation sequencing has been shown to accelerate gene discovery in human disease. However, our confidence in the correct disease-associations of rare variants continues to depend on functional analysis. Here, we employ a sensitive assay of human FGF8 variants in zebrafish to demonstrate that the spectrum of isoforms of FGF8 produced by alternative splicing can provide key insights into the genetic susceptibility to human malformations. In addition, we describe novel mutations in the FGF core structure that have both subtle and profound effects on ligand posttranslational processing and biological activity. Finally, we solve a case of apparent digenic inheritance of novel variants in SHH and FGF8, two genes known to functionally coregulate each other in the developing forebrain, as a simpler case of FGF8 diminished function.
Introduction
Holoprosencephaly (HPE) is anatomically distinguished from other midline malformations of the brain by the degree of separation of the eye field and telencephalon into discrete left and right structures. The phenotypic spectrum can range from mild craniofacial features, such as closely spaced eyes or solitary median central incisor, to the extreme of severe microcephaly, cyclopia and a proboscis (1) . Molecularly similar and even identical mutations can be associated with either end of the phenotypic spectrum. In utero, HPE can be observed in 1:250 otherwise normal pregnancies but most affected fetuses fail to survive to term (2, 3) . HPE (due to mutations in SHH, FGFR1, FGF8 and other genes) is presently considered distinct from disturbances of the hypothalamic-pituitary axis [Kallmann syndrome, idiopathic hypothalamic hypogonadism (IHH); FGFR1, FGF8, HESX1, GLI2, others], cleft lip and palate (CL/P) (FGF8, others), Culler-Jones syndrome (GLI2) and from septo-optic dysplasia (regulatory SHH variants, HESX1, others). However, we now appreciate that many of the causative genes and environmental teratogens are shared between these conditions (4) (5) (6) (7) (8) (9) (10) . All of these conditions can demonstrate (1) similar prevalence rates in human populations; (2) incomplete penetrance; (3) variable expressivity and (4) have proponents for oligogenic or digenetic inheritance patterns (11, 12) ; as well as (5) a suspected role for environmental modifiers (13, 14) . Interestingly, some of the very same mutations can be observed among probands classified with entirely different syndromes (4, 15) (this study).
Detailed analysis of the murine locus for Fgf8 defined a gene with a key role in body plan specification, tissue growth, differentiation, the epithelial/mesenchymal transition of epiblast cells that ingress into the primitive streak, the specification of the organizer and its axial mesendoderm derivatives, as well as participating in cooperative actions between several distinct patterning centers within the brain, face and limbs (16) (17) (18) (19) (20) (21) (22) (23) . Its coding region produces multiple isoforms through alternative splicing that encode proteins with distinct biological activities attributed to differential receptor binding affinity (23) (24) (25) (26) (27) . The most potent of these isoforms, Fgf8b, is indispensable for early development of the mouse and cannot be compensated for by the expression of either other FGF ligands or alternative Fgf8 isoforms (27) (28) (29) . Furthermore, progressively severe phenotypes can be observed in mice with decreased levels of functional protein (30) (31) (32) . Different tissue fields are impacted differently by such decreased signaling activity. For example, while both FGFR1 and FGF8 are strongly implicated in IHH pathogenesis, these patients rarely have limb anomalies. Although dominant negative mutations in FGFR1 can perturb both tissues (33) . Consequently, it is not hard to imagine that mutations at the human FGF8 locus can lead to a spectrum of distinct phenotypic consequences due to the strength of the mutation and the actions of comorbid factors.
In humans, the first report of novel mutations in FGF8 involved an isolated case of CL/P (34). Subsequently, mutations in either FGFR1 or FGF8 (occasionally both) were identified in human patients (IHH) with/or without anosmia (Kallmann syndrome, which is a form of IHH with absent sense of smell) (4, (35) (36) (37) (38) . Experimental studies in mice confirm a role for both genes in the specification of the gonadotropin-releasing hormone secreting neurons in the hypothalamus and the development of the optic chiasm (39) and olfactory bulb (40) . Although a potential role for FGF8 variants in HPE has been previously suggested (41), the detected variation had only minor functional disturbances, was also seen among IHH patients (35) and subsequently also among healthy controls (ExAC).
In this study, we set out to establish the role of FGF signaling in the pathogenesis of HPE using assays first developed in our analysis of Hartsfield syndrome (33, 42, 43) . Recent studies have claimed a major role for FGF signaling in HPE, although functional studies were not provided to support their claims (15, 36) . Therefore, from a set of 330 HPE probands evaluated using a targeted capture panel of 150 developmental genes we selected 14 variants for further bioinformatics and functional analysis: two INDEL (one as a published positive control) (33) , three novel putative splicing variants, one new autosomal recessive variant, one published autosomal recessive variant (36) , two control SNPs seen in healthy individuals and five rare missense variants (Table 1; Roessler et al., manuscript in preparation). Here, we show that the application of functional testing brings considerable clarity to the genotype/phenotype analysis and affirms many of the original pathogenetic assertions.
Results

Alternative splicing of human FGF8 affects its biological activity
The exonic structure and genomic organization of the Fgf8 gene is highly similar from teleosts to mammals, with the most important differences being limited primarily to variable exon usage at the amino-terminus (Supplementary Material, Table S1 ). In higher vertebrates, e.g. mouse and human, there is a variably utilized exon 1c that is absent in the most commonly tested isoforms (Fgfa and Fgfb) and the genomes of chick, frogs and zebrafish. This variable exon 1c is the site of numerous variants of unknown significance ( Table 1) . The physiological function of the first two exons (1a and 1b) is to encode the signal peptide that is required for efficient secretion of the signaling molecule. In mice, there is also an extended version of exon 1b that allows for the expression of eight isoforms through alternative splicing. In humans, there is a stop codon in this extended murine version of exon 1b that reduces the number of isoforms to only four (FGFa, FGF8b, FGF8e and FGF8f) (Supplementary Material, Fig. S1 ). For the purpose of mutation screening, we looked for variants in all six coding exons (1a, 1b, 1c, 1d [long] that completely overlaps exon 1d[short], exon 2 and exon 3).
Various experimental assays have previously established that the variable usage of alternative exon 1d splice acceptor sites can dramatically change the biological activity of Fgf8 isoforms, both in vitro and in vivo (29) . As shown in Figure 1 , this difference is also detected when we express the two longest human FGF8 isoforms (e versus f) in zebrafish. For the purpose of determining the relative biological response of FGF8 protein variants (Table 1) , we used the core structure of FGF8e (encoding exon 1c and 1d[short]). Our variant numbering reflects this choice as the wild-type (wt) isoform (NM_033164.3). The RNA injection-induced extreme toxicity (dorsalization and dead embryos) of the FGFf form effectively precluded its use as an efficient assay system in this study. This more potent f isoform was toxic at all doses tested. In contrast, using the FGF8e form showed a more moderate toxicity as a function of increasing RNA dose. Since we wanted to maximize our ability to measure less than wt biological activity differences, we selected the FGF8e cDNA backbone for site-directed mutagenesis. In doing so, we can show that using a 0.4 pg of FGF8e mRNA dose allowed us to measure a broader range of variant activity by measuring both a ratio of dorsalization/dead (50%) in our phenotypic scoring (see all doses tested) and also when compared with the use of 0.2 or 0.3 pg of the FGF8f isoform (Fig. 1B) . Since the gene organization (and sequence context of the splice sites) is identical between murine Fgf8 and human FGF8, we used bioinformatics analysis to interpret the consequences of mutations within or adjacent to the 1d[long] splice acceptor site (Supplementary Material, Table S1 ). As shown in Figure 1A (and described in Table S1 ) (33) . Among HPE patients this variable exon 1c is also a common location of sequence variation ( Table 1 ). The p.R28S, p.P30_A31insSAGPLP and p.R44W variants are all indistinguishable from wt in our functional assay system suggesting that their presence (or absence) in any of the isoforms contributes little to the biological effects ( Fig. 2) . Among our HPE patients, we identified two novel sequential basepair variants in the invariant À1 position of acceptor site 1d[long] and the adjacent þ1 position of the first codon (p.V53L) of 1d [long] . This clustering is remarkable given that no splice site variants are described among the 60 000 healthy controls in ExAC databases. Furthermore, four independent splicing analysis tools (Supplementary Material, Table S1 ) support the skipping of this acceptor site (f isoform) for its downstream alternative (e isoform). Therefore, we infer that these sequence changes are equivalent to those artificially created in murine knock-in models and impose a haploinsufficiency on these probands for FGF8b activity. Similarly, the invariant splice donor site for IVS2þ1[G>A] is predicted to affect all four FGF8 isoforms and is also likely a loss-of-function allele. Any aberrant splicing between exons 2 and 3 inevitably alters the structure of the core receptor binding domain and heparin binding domain CDD: 238015.
As a negative control, we tested the p.E56Q variant that was novel but detected in a healthy individual without HPE. The overexpression of this variant in zebrafish is equivalent to the phenotypic and marker induction effects of the wt form ( Fig. 2C and D) . In contrast, the p.T108M variant was a complete loss-of-function allele with no dorsalizing activity, no marker induction properties, despite normal protein expression (compare Fig. 2C-E) . The effects of the SHH p.S156R variant are described later (Fig. 4) . Interestingly, the same molecular alteration has recently been described in a patient with semilobar HPE and a comorbid obligate deleterious splicing variant in FGFR1 (15) . Furthermore, the identical FGFR1 splicing variant was first described in a patient with Kallmann syndrome which tends to blur the distinctions between these apparently unrelated conditions (4).
Autosomal recessive HPE is uncommon
Consanguinity is uncommon in our patient population but when present clearly has been described to predispose probands to autosomal recessive gene combinations (45) . In our subject cohort, we observed a single case of homozygosity of a novel variant in the core receptor binding domain of FGF8. This p.T122M variant was assessed in our functional assay and determined to be a hypomorph and is, to our knowledge, the first experimentally confirmed case of homozygous recessive inheritance of FGF8 variants in HPE (Fig. 2C) . Therefore, caution should be used to interpret novel variants in the homozygous state unless strong evidence of consistent transmission within a pedigree or the results of functional analysis are also considered (46, 47) . However, we can now provide support for a second instance of autosomal recessive inheritance of a FGF8 variant (36), p.R178H, in HPE by using our functional assay to illustrate its utility (Fig. 2) .
Different amino acid substitutions within a codon can have distinct effects
At the amino acid position p.V146 within the receptor binding core domain of FGF8 healthy individuals can have a rare substitution of isoleucine for valine. Such a variation is predicted by biochemistry and bioinformatics to be benign and indeed functional analysis confirms this prediction. However, substitution with a phenylalanine residue at this same position dramatically reduces the biological response of the mutant form (Fig. 2C) . Although we suspect that this is due to altered receptor binding between the mutant form and its receptor partner, binding studies have not yet been performed. Interestingly, this patient has semilobar HPE and a genetic workup revealed normal chromosomes, normal microarray, normal four gene screen analysis (Table 1 ) and no comorbid variants in the targeted capture panel (data not shown).
Sequence variants can perturb glycosylation and inhibit biological activity
We have previously demonstrated that in-frame deletions within the heparin binding domain can interfere with FGF8 function (variant c.515-529delCCCGCAAGGGCCGGC in Table 1 , Fig. 1, described in 33) . This variant confirms that Fgf ligands can use heparin sulfate glycoproteins as coreceptors in physiological interactions. We now show that glycosylation of the FGF8 ligand itself can influence bioactivity. The p.N155S variant was identified in an anonymized Brazilian cohort of HPE patients added to our analysis to boost statistical power (Roessler et al., manuscript in preparation). This variant is also seen once in ExAC databases. We noticed that the variant Representative comparisons are shown between FGF8e and FGF8f followed by whole mount in situ hybridization at 8 h after fertilization. Quantification data in this study are described in Supplementary Material, Table S2. occurs within a consensus N-glycosylation site (N-any amino acid-S/T). Synthetic constructs were made for the observed mutation p.N155S, an alternative substitution p.N155I and a control variant p.T157A. All three variants eliminate the consensus glycosylation site and alter the migration of the posttranslational protein products in transfected Cos7 and HEK293 cells ( Fig. 3A and C) . The wt Flag-tagged FGF8e, with an intact glycosylation site, is observed as a dimer on western blots of transfected cell lines. The slower migrating band is sensitive to PNGase F or endo H enzymatic cleavage (Fig. 3B ). This result confirms that the genetic modification at positions p.155 and p.157 are indeed interfering with glycosylation in vivo. Interestingly, several sequence variations within this glycosylation site affect the bioactivity of the FGF8 molecule (Fig. 3D) . The phenotypic effects of the p.N155S variant are yet to be fully documented.
Detection of comorbid variants does not prove oligogenic or digenic models
Although defective hedgehog signaling was nearly simultaneously discovered to cause HPE, first as cyclopia in the mouse (48) and then HPE in humans (49, 50) there have been relatively few studies to determine the functional effects of various mutations (51). The hedgehog gene encodes two critical parts: the signaling functions are entirely due to the highly conserved while hypomorphic activity is somewhere between these extremes (middle panel; FGF8e V146F, N155S, R178H). (E) Western blot of FGF8 variants within the receptor binding domain region that demonstrate variable bioactivity. All constructs were tagged with Flag and transfected into Cos7 cell line and b-actin was used as loading control. Note that p.N155S migrates slightly faster (Fig. 3) . Quantification data in this study are described in Supplementary Material, Table S2 .
amino-terminal domain that is dually lipidated by palmitate (52) and cholesterol, with the latter being an autocatalytic addition by the carboxy-terminal Hint motif (Fig. 4A) (53, 54) . Most mutations seen in the signaling domain are novel and often Quantitative measurements of control (gfp), wt and variants SHH-injected embryos. Yellow represents embryos with a normal phenotype and gray is for small eye (microphthalmia) embryos. Error bars represent SEM, *** indicates P < 0.001 when compared with SHH wt based on Student t-test. Quantification data in this study are described in Supplementary Material, Table S2 .
constructs p.N155I and p.T157A scored as loss-of-function in contemporaneous experiments. We conclude that glycosylation has subtle effects on bioactivity that can be profound in certain circumstances. Error bars represent SEM, * indicates P < 0.05 and ** indicates P < 0.01 when compared with FGF8e wt Flag based on Student t-test. Quantification data in this study are described in Supplementary Material, Table S2 .
meet the criteria for pathogenicity without the support of functional studies. Here, we illustrate the need for caution in these interpretations. Patient BL9037 (Table 1) has inherited a novel complete lossof-function mutation in FGF8 (p.T108M) from one parent and a novel suspected loss-of-function mutation in SHH (p.S156R) from the other parent. At first glance, this appears to be a clear case of digenic inheritance. The p.T108M has been previously implicated in HPE (15) and proven to abnormal in our functional assays (see earlier). The comorbid SHH variant is also novel and occurs at a surface residue that experimentally is associated with binding to the tumor repressor PTCH1 (55-58). Binding to PTCH1 is a prerequisite for hedgehog pathway activation (59) . Furthermore, Fgf8 signals from the rostral signaling center are required to maintain the ventral signaling center responsible for eye field and telencephalic separation (principally hedgehog signals, see earlier) (31, 32) .
To determine the potential effects of variants in SHH, we performed an overexpression assay in zebrafish. At 28 h, zebrafish injected with the wt SHH full-length cDNA construct produces visibly reduced eyes (Fig. 4B ) that can be scored and counted as a consistent bioassay measurement (Fig. 4C) . In zebrafish, shh RNA injection causing a small eye phenotype has been previously described (60, 61) . As controls, we chose a point mutation at the site of cholesterol addition (p.C198S; known hypomorph) and the carboxy-terminal loss-of-function variant (p.T267I; both controls documented in 62). Under our assay conditions, the p.S156R variant is clearly normal. The control constructs closely resemble the hypomorphic and loss-of-function phenotypes previously published.
Discussion
The hedgehog signals (among others) necessary for the separation of the eye field and forebrain must act at the correct midline position, in the correct amount and at the correct time to correlate with normal development. The best understood causes of HPE affect one or more of these requirements. Rostral FGF signaling now emerges as a prerequisite for this midline signaling program. These functions are in addition to its earlier roles during gastrulation and later roles in craniofacial structures, the gut and limbs. We now appreciate that there is a positive feedback loop with the ventral midline hedgehog activity that induces NKX2.1, promotes FOXG1 expression and forebrain growth, FGF provides key inhibitory actions on the dorsal signaling center (BMP, WNTs) that oppose ventral specification and promote dorsal structures of the cortical hem. This sophisticated cross talk between signaling centers is extremely sensitive to gene dose and small changes can have conflicting or confounding consequences (31, 32) . Assuming the critical window of HPE sensitivity is passed successfully, the development of the optic tracts, the retina and pigment epithelium, olfactory bulbs, pituitary and craniofacial structures may yet be perturbed by defects in FGF function. Hence, the phenotypic spectrum of coding (or non-coding) variation at the FGF8 locus can have consequences for the development of all of these structures.
In this study, we provide compelling evidence that abnormal FGF8 function can contribute to HPE. In many of our cases, there are no obvious comorbid gene alterations that suggest the necessity of either oligogenic or digenic cooperativity. Nevertheless, it is important to keep an open mind while further cases are analyzed and reported. Continued examination using functional analysis will help to deemphasize variants of unknown significance (44) (this study). To our knowledge, only FGFR1 mutations are commonly de novo (33, 42, 43) . None of our FGF8 mutations are documented to be de novo, although most are novel. Spontaneously novel microdeletion of the FGF8 locus causes a contiguous gene deletion syndrome that supports the association with HPE and CL/P (63) . Similarly, while not yet tested in our assay, the p.D73H (NP_149353.1) associated with CL/P is likely damaging by structural arguments and is also de novo (34) .
Perhaps the most interesting observation from our study is that, although exceedingly uncommon, the same molecular variations are reported in diverse midline malformation syndromes. This is true for a complete loss-of-function in FGF8 (p.T108M) in two unrelated patients with semilobar HPE. One had a second mutation in FGFR1 that was absent in our patient (15) but previously described in Kallmann syndrome (4) . In this report, a p.P129* stop codon mutation was described in a patient with HPE. Interestingly, this same alteration has previously been reported in IHH (64) . The detection of the same variant in different contexts as inherited risk factors helps to support either reduced penetrance, variable expressivity or both. Oligogenic or digenic models are also not excluded and may help to explain these effects. The unmeasured role of environmental factors is an additional consideration that must be explored and validated. We maintain that comprehensive clinical examination, accurate phenotypic reporting, accurate sequencing with verification, combined with comprehensive data sharing will foster increased understanding and more accurate genetic counseling for our patients.
Materials and Methods
Patient samples and informed consent
All subjects provided informed consent for themselves and their affected children using approved forms and oversight from our NIH, NHGRI Institutional Review Board. Anonymous samples were obtained from our Brazilian colleagues by full-status collaboration, informed consent review and a total of 50 anonymous cases were added via an amendment to our larger Flagship study (Roessler et al., manuscript in preparation). Institutional approval has been obtained for data sharing with investigators studying brain development and HPE. Medically relevant FGF8 or SHH variants have been deposited into ClinVar.
Expression constructs
The FGF8 cDNA, transcript variant e-form (NM_033164.3) has been described (29) and f-form (NM_033163.3) was purchased from (OriGene Technologies, Rockville, MD). All FGF8 constructs were subcloned into the pCS2þ vector after PCR from cDNA resulting from clonal template purification. For western blot analysis, the indicated FGF8 clones are tagged with Flag DNA sequences. The wt and mutant forms of SHH clones were also subcloned into a pCS2þ expression vector. The site-directed mutagenesis of FGF8 and SHH performed according to instructions from company without modification (Agilent Technologies, Santa Clara, CA). All subcloned cDNA constructs were verified by Sanger sequencing.
Zebrafish husbandry
Wild-TAB5 strain was used in this study. The tropical zebrafish were maintained at 28 C according to: The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish (Danio rerio). All experimental procedures have been approved and performed by following procedures described in our National Human Genome Research Institute animal protocol at the National Institutes of Health.
In vitro transcription and mRNA injection
The messenger RNA was generated using the mMESSAGE mMACHINE SP6 transcription kit (Thermo Fisher Scientific, Waltham, MA). A 0.4 pg bolus of FGF8 synthetic mRNA was injected into fertilized one-cell stage embryos. To test the splicing effects on FGF8, 0.1-0.4 pg of e-FGF8, f-FGF8 mRNA was introduced into embryos. A 10 pg bolus of SHH synthetic mRNA was injected to induce the small eye (microphthalmia) phenotype. All experimental tests of mRNA injections in this study were performed in triplicate and on different days. Quantification of embryos by phenotypic class can found in Supplementary Material, Table S2 .
In situ hybridization
Antisense RNA probes were transcribed by SP6/T7 Transcription kit (Sigma-Aldrich, Saint Louis, MO). Whole mount in situ hybridization was performed as previously described (33) and were performed in triplicate. Molecular marker dusp6 (33) was used as downstream biomarker of FGF signaling.
Transfection and immunoblot analysis
A total of 500 ng of Flag-tagged FGF8 cDNA was transfected into HEK293 and Cos7 cell using a lipofectamine 2000 transfection reagent kit (Thermo Fisher Scientific) in 12-well tissue culture wells and the analysis has been done three times. After 24 h, cell lysis was performed with 200 ll of lysis buffer [20 mM TrisHCl (pH 7.5) 150 mM NaCl, 1% TritonX-100] supplemented with a protease inhibitor cocktail (Thermo Fisher Scientific). For western blot analysis, 10% volume of lysate has been used for analysis. Primary antibody for this study was anti-Flag Mab (Sigma-Aldrich) and b-actin Mab (GeneTex, Irvine, CA) and secondary antibody was anti-rabbit IgG HRP (Cell Signaling, Danvers, MA) for Flag and anti-mouse IgG HRP (GeneTex) for b-actin antibody.
N-glycosylation assay
For the N-glycosylation test, Flag-tagged constructs were transfected into HEK293 and Cos7 cells. N-glycosylation assay has been done three times with both HEK293 and Cos7 cells. A 9 ll of whole lysate was used for analysis after lysis [20 mM Tris-HCl (pH.7.5) 150 mM NaCl, 1% TritonX-100] supplemented with protease inhibitor cocktail (Thermo Fisher Scientific). PNGase F and Endo H (New England Biolabs) enzyme methods were tested in this study by following the manufacture guidelines. Enzyme treatment was performed to full digestion during a 1 h incubation at 37 C.
Statistical analysis
All RNA injections are performed on different days and in three independent injections. For statistical analysis, experimental data was calculated with two-tailed Student t-test using Microsoft Excel 2010. Error bars on graphs are means (SEM).
